Although ALK TKIs yield high response rates (>60%) in advanced ALK‐positive NSCLC,3, 4, 5 patients who initially respond to these agents eventually experience resistance and disease progression.6 For patients who progress after ALK TKI therapy, initial cytotoxic chemotherapy regimens, which are used for first‐line treatment of NSCLC (e.g., carboplatin/paclitaxel), are recommended.6 The gene discussed is ALK; the disease is non-small cell lung carcinoma.